New York is currently home to 4447 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New York, Rochester, Bronx and Buffalo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study of Ruxolitinib and Duvelisib in People With Lymphoma
Recruiting
This study will test the safety of ruxolitinib, given at one dose that does not change, and duvelisib, given at different doses, to find out what effects, if any, the study treatment has on people with relapsed or refractory NK-cell or T-cell lymphoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/06/2025
Locations: Memorial Sloan Kettering Commack (Limited Protocol Activities), Commack, New York
Conditions: T-cell Lymphomas, NK-Cell Lymphomas, T-cell Prolymphocytic Leukemia, T-cell Large Granular Lymphocyte Leukemia
Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer
Recruiting
Background: Cisplatin is used to treat head and neck cancer. People who take this drug are at risk for hearing loss. Atorvastatin is a drug used to treat high cholesterol. It might reduce the risk of cisplatin-induced hearing loss. Objective: To find out if atorvastatin reduces hearing loss in people treated with cisplatin and radiation. Eligibility: People ages 18 and older with squamous cell carcinoma of the head and neck who will undergo treatment with cisplatin-based chemotherapy and ra... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
02/06/2025
Locations: Wilmot Cancer Institute at the University of Rochester Medical Center in New Yor, Rochester, New York
Conditions: Hearing Loss, Head and Neck Cancer
GDNF Gene Therapy for Multiple System Atrophy
Recruiting
The objective of this randomized, double-blinded, placebo-controlled Phase 1 investigation is to evaluate the safety and potential clinical effect of AAV2-GDNF delivered to the putamen in subjects with either a possible or probable diagnosis of Multiple System Atrophy.
Gender:
ALL
Ages:
Between 35 years and 75 years
Trial Updated:
02/06/2025
Locations: NYU Langone Health, New York, New York
Conditions: Multiple System Atrophy
The Use of Nanoparticles to Guide the Surgical Treatment of Prostate Cancer
Recruiting
The purpose of this study is to see whether using the 64Cu-NOTA-PSMA-PEG-Cy5.5-C' dot tracer is a safe way to identify tumor cells before and during surgery for prostate cancer. The researchers want to find out whether PET/MRI scans done after the injection of this investigational tracer are more accurate than the usual imaging scans used to locate deposits of prostate tumor cells. The researchers will study how the tracer travels through your body and where it is distributed. This study is the... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
02/06/2025
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Prostate Cancer
Treatment of Focal Ventricular Tachycardias Using a Pulsed Field Ablation From a Point Ablation Catheter Short Title FOCUS-PFA
Recruiting
The purpose of this study is to examine the use of a point ablation catheter (Farapoint, Boston Scientific) in the mapping and ablation of focal ventricular arrhythmias (premature ventricular contractions or ventricular tachycardia) using pulsed field energy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: Icahn School of Medicine at Mount Sinai, New York, New York
Conditions: Focal Ventricular Arrhythmias, Premature Ventricular Contractions, Ventricular Tachycardias
Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa
Recruiting
The study duration for an individual subject includes screening (14 days), the treatment period (28 days) and the observational follow-up period of 28 days, in total 70 days ± 6 days. All subjects will receive IMP for 28 days followed by one End of Study (EOS) visit, 4 weeks after EOT visit.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
02/05/2025
Locations: Forest Hills Dermatology Group, Kew Gardens, New York
Conditions: Chronic Urticaria, Idiopathic, Hidradenitis, Hidradenitis Suppurativa
Transforming Care for Individuals with Childhood-onset Systemic Lupus Erythematosus
Recruiting
This study aims to investigate the feasibility and effectiveness of a cognitive behavioral coping skills program, Treatment and Education Approach for Childhood-onset Lupus (TEACH), for youth with cSLE when integrated into medical care. This TEACH program aims to teach participants skills in order to cope with fatigue, pain, and depressive symptoms--symptoms that commonly affect adolescents and young adults with lupus.
Gender:
ALL
Ages:
Between 12 years and 22 years
Trial Updated:
02/05/2025
Locations: Montefiore Medical Center, Bronx, New York
Conditions: Systemic Lupus Erythematosus of Childhood (Disorder)
Open-label, Dose Escalation Study of Safety and Preliminary Efficacy of TN-401 in Adults with PKP2 Mutation-associated ARVC
Recruiting
This first-in-human study is designed to evaluate the safety, and preliminary efficacy (PD) of TN-401 gene therapy in adult patients with symptomatic PKP2 mutation-associated ARVC.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/05/2025
Locations: NYU Langone Health, New York, New York
Conditions: Arrhythmogenic Right Ventricular Cardiomyopathy
The SUGAR Study; SBRT and Relugolix) for Prostate Cancer
Recruiting
The goal of this clinical trial is to measure the toxicity and effectiveness of the following treatments for cFIR/cgUIR prostate cancer patients. Stereotactic body radiotherapy (SBRT) alone or Stereotactic body radiotherapy (SBRT) combined with Ultrashort GNRH Antagonist called Relugolix (an oral drug). Treatments will be randomly assigned to study patients. The main questions it aims to answer are the following: 1. Whether the proportion of men who undergo SUGAR have a superior rate of attai... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Prostate Cancer
PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III
Recruiting
This is a prospective, multi-center, open label, randomized control clinical trial evaluating the safety and efficacy of the Cordella™ Pulmonary Artery Sensor System in NYHA Class II-III Heart Failure Patients (PROACTIVE-HF-2 Trial). The study contains of 5 arms: NYHA II Cohort - To demonstrate safety and efficacy of the Cordella PA Sensor System in NYHA Class II HF patients, where patients have daily access to PAP data. * Treatment Arm (Group 1) * Active Control Arm (Group 2) * Crossover Arm... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: Mount Sinai West, New York, New York
Conditions: Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure
LIVEBETTER: A Trial Comparing Medications in Older Adults With Stable Angina and Multiple Chronic Conditions
Recruiting
To establish the effectiveness and tolerability of standard of care anti-anginal treatment (beta-blocker and calcium channel blocker medications) in older adults with symptomatic Stable Ischemic Heart Disease (SIHD) and multiple chronic conditions (MCC).
Gender:
ALL
Ages:
65 years and above
Trial Updated:
02/05/2025
Locations: Mt. Sinai Health System, New York, New York
Conditions: Angina, Stable Ischemic Heart Disease
Comparison of Two Pulmonary Embolism Treatments
Recruiting
The primary objective of this trial is to evaluate the safety and efficacy of treatment with anticoagulation alone versus anticoagulation and mechanical aspiration thrombectomy with the Indigo Aspiration System for the treatment of intermediate-high risk acute pulmonary embolism (PE).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/05/2025
Locations: Mount Sinai Hospital, New York, New York
Conditions: Pulmonary Embolism Acute